News

Cassava Sciences Welcomes Dawn C. Bir to Board of Directors

Cassava Sciences Welcomes Dawn C. Bir to Board of Directors

Cassava Sciences Enhances Leadership with New Board Appointment

Cassava Sciences, Inc. (NASDAQ: SAVA), a biotechnology company devoted to creating innovative treatments for central nervous system (CNS) disorders, announced recently that Ms. Dawn C. Bir has been appointed to its Board of Directors.

Ms. Dawn C. Bir: A Proven Biopharmaceutical Leader

Dawn Bir brings extensive experience to Cassava, having previously helped guide several biopharmaceutical companies through significant growth and transition phases. Her background includes key executive roles at notable organizations like Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics, demonstrating a strong ability to drive both clinical and commercial success.

Creating Shareholder Value

Claude Nicaise, MD, Chairman of the Board at Cassava, expressed enthusiasm about Ms. Bir's addition to the leadership team during a transformative time for the company. He stated, "Her commitment to enhancing shareholder value will be a valuable asset, and we eagerly anticipate the positive impact of her contributions.”

Preparing for Clinical Advancements

As Cassava readies itself for the initiation of its first clinical study of simufilam targeting TSC-related epilepsy, Rick Barry, the company's President and CEO, emphasized the need for strategic capabilities within the Board. He noted Ms. Bir's proven track record in establishing impactful relationships within the industry would be crucial as they advance their programs.

A Call to Action in CNS Research

Ms. Bir echoed this sentiment, highlighting the urgent need for new therapeutic options for TSC-related epilepsy. She expressed her excitement about working closely with Cassava’s committed management team to navigate the company’s business and clinical strategies, aiming to deliver significant advancements in treatment options for patients and their families.

About Cassava Sciences, Inc.

Cassava Sciences (NASDAQ: SAVA) is focused on innovative treatment solutions like simufilam for CNS disorders, including TSC-related epilepsy. Simufilam is a proprietary oral small molecule that aims to modulate the activity of the filamin A protein, which plays a vital role in neuronal development. The company's base of operations is located in Austin, Texas.

Contact Information

For further inquiries, interested parties can reach out to:
Investors:
Sandya von der Weid
Email: svonderweid@lifesciadvisors.com
Company:
Eric Schoen, Chief Financial Officer
(512) 501-2450
Email: ESchoen@CassavaSciences.com
IR@cassavasciences.com

Frequently Asked Questions

What is the main focus of Cassava Sciences?

Cassava Sciences is dedicated to developing novel treatments for central nervous system disorders, including epilepsy associated with Tuberous Sclerosis Complex.

Who is Dawn C. Bir?

Dawn C. Bir is a seasoned biopharmaceutical executive, newly appointed to the Board of Directors at Cassava Sciences.

What role does the Board play in Cassava's strategy?

The Board provides strategic oversight and direction, particularly as the company prepares for clinical advancements in their product pipeline.

What is simufilam?

Simufilam is an investigational treatment currently being developed by Cassava Sciences for TSC-related epilepsy and other CNS disorders.

How can investors contact Cassava Sciences?

Investors can reach out to the CFO via email at ESchoen@CassavaSciences.com for inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

WeightWatchers Shifts 2025 Earnings Call for Key Accounting Updates

Updated Category News Views 154

WeightWatchers Adjusts Schedule for 2025 Earnings Report WW International, Inc. (NASDAQ: WW), widely recognized for its innovative weight management solutions, has made an important change regarding its upcoming earnings report. The company has rescheduled its earnings release and associated conference call originally intended for August 5, 2025. This Rescheduling is...

Continue Reading
Investors Alert: Key Investigations into Regeneron Pharmaceuticals

Updated Category News Views 120

Investors Take Note: Faruqi & Faruqi Seeks to Help Faruqi & Faruqi, LLP, a prominent national securities litigation firm, is leading an investigation focusing on investors who may have sustained significant losses with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The firm encourages those who believe they have suffered losses of over $100,000 due to the company’s...

Continue Reading
Waller's Bold Critique of Powell: A Call for Rate Cuts

Updated Category News Views 233

Waller’s Challenge to Economic Caution Federal Reserve Governor Christopher Waller has made headlines by challenging the stance of Chairman Jerome Powell, particularly regarding his assertion that economic data is too sparse to draw clear conclusions. Waller believes the Fed should proceed with easing monetary policy, even amidst perceived gaps in information. Ending...

Continue Reading
Michael John Politis Recognized as Elite Attorney in America

Updated Category News Views 276

Michael John Politis Achieves National Recognition Michael John Politis, a distinguished attorney at Politis & Matovina, P.A., has garnered significant acclaim by being recognized as a member of the Nation's Top One Percent. This prestigious acknowledgment is bestowed by the National Association of Distinguished Counsel (NADC). The NADC is committed to upholding the...

Continue Reading
Home Buying Opportunities: Navigating the Market's Shift

Updated Category News Views 74

Introduction For many home buyers, fall typically signals a slow down in the housing market. But this year, things might unfold differently. With mortgage rates dropping and inventory on the rise, buyers could have a chance to find their dream homes during what is usually seen as the offseason. Affordability Improves The recent decline in monthly mortgage payments has...

Continue Reading